Lymphoma

Opdivo had promising response rates in a recent trial testing the treatment in patients with relapsed or refractory Hodgkin lymphoma.

Pairing two drugs that have shown to be effective in treating lymphoma might be the next step for mantle cell lymphoma treatment.

When we are surviving cancer, when we want to see everybody else survive it too, another death is hard to take. When somebody passes, we are reminded of our own mortality—and distant losses—even as we mourn. Poetry helps.

Peter Martin, M.D., discusses the evolving field of mantle cell lymphoma treatment.

Axicabtagene ciloleucel (KTE-C19; axi-cel) was granted a priority review by the Food and Drug Administration (FDA) for the treatment of transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma (NHL).

There is currently no uniform procedure for patients with double-hit lymphoma (DHL) that prolongs benefit. Some patients receive autologous stem-cell transplantation to reduce the risk of relapse, but the jury is still out on the impact that it has.

Copanlisib was granted a priority review designation by the Food and Drug Administratioin (FDA) for the treatment of patients with relapsed/refractory follicular lymphoma who had at least two therapies beforehand, according to Bayer, the manufacturer of the drug.

There were nearly identical response rates and toxicity with subcutaneous administration of Rituxan (rituximab) and IV administration of the drug to treat follicular lymphoma in the first-line setting, according to results from the phase 3 SABRINA trial that were published in The Lancet Haematology.

Experts discuss how to have the best chances for a complete response for patients with chronic lymphocytic leukemia (CLL) who developed Hodgkin lymphoma (HL).

Grzegorz S. Nowakowski, M.D., discusses the potential for genetic testing for patients with mantle cell lymphoma.

How I saved big on costly prescription medications for cancer treatment.

A mantle cell lymphoma survivor discusses being a transplant patient.

The medications that help patients can be dangerous in combination if not closely monitored.

Finding normalcy after cancer.

Novel combinations may be on the rise for the treatment of mantle cell lymphoma.

How food can trigger memories and emotions.

A non-runner explains why running and cancer are the same thing. Except they're not.

Jessica Yasmine Islam, M.P.H., discusses the changing statistics behind people with HIV and cancer.

"Neither feels guilty about surviving — although both have had plenty of reminders that they’re dealing with cancer — and both have found ways to continue enjoying life."

Andre Goy, M.D., discusses some exciting advances in mantle cell lymphoma (MCL).

All members of the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted to approve Rituxan for the treatment of some blood cancers.

Breast implants, especially those with textured surfaces, may be associated with a rare type of lymphoma, according to a recent statement by the Food and Drug Administration (FDA).

Jim Kochenderfer, M.D., lends insight to the future of CAR T-cell therapy for hematologic malignancies.

How the side effects of radiation therapy almost killed me, and kept me from eating turkey.